Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18,749 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Dardaei L, Wang HQ, Singh M, Fordjour P, Shaw KX, Yoda S, Kerr G, Yu K, Liang J, Cao Y, Chen Y, Lawrence MS, Langenbucher A, Gainor JF, Friboulet L, Dagogo-Jack I, Myers DT, Labrot E, Ruddy D, Parks M, Lee D, DiCecca RH, Moody S, Hao H, Mohseni M, LaMarche M, Williams J, Hoffmaster K, Caponigro G, Shaw AT, Hata AN, Benes CH, Li F, Engelman JA. Dardaei L, et al. Among authors: williams j. Nat Med. 2018 May;24(4):512-517. doi: 10.1038/nm.4497. Epub 2018 Mar 5. Nat Med. 2018. PMID: 29505033 Free PMC article.
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C, Lu H, Wang H, Loo A, Zhang X, Yang G, Kowal C, Delach S, Wang Y, Goldoni S, Hastings WD, Wong K, Gao H, Meyer MJ, Moody SE, LaMarche MJ, Engelman JA, Williams JA, Hammerman PS, Abrams TJ, Mohseni M, Caponigro G, Hao HX. Liu C, et al. Among authors: williams ja. Clin Cancer Res. 2021 Jan 1;27(1):342-354. doi: 10.1158/1078-0432.CCR-20-2718. Epub 2020 Oct 12. Clin Cancer Res. 2021. PMID: 33046519
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.
Krall EB, Wang B, Munoz DM, Ilic N, Raghavan S, Niederst MJ, Yu K, Ruddy DA, Aguirre AJ, Kim JW, Redig AJ, Gainor JF, Williams JA, Asara JM, Doench JG, Janne PA, Shaw AT, McDonald Iii RE, Engelman JA, Stegmeier F, Schlabach MR, Hahn WC. Krall EB, et al. Among authors: williams ja. Elife. 2017 Feb 1;6:e18970. doi: 10.7554/eLife.18970. Elife. 2017. PMID: 28145866 Free PMC article.
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Hao HX, Wang H, Liu C, Kovats S, Velazquez R, Lu H, Pant B, Shirley M, Meyer MJ, Pu M, Lim J, Fleming M, Alexander L, Farsidjani A, LaMarche MJ, Moody S, Silver SJ, Caponigro G, Stuart DD, Abrams TJ, Hammerman PS, Williams J, Engelman JA, Goldoni S, Mohseni M. Hao HX, et al. Among authors: williams j. Mol Cancer Ther. 2019 Dec;18(12):2368-2380. doi: 10.1158/1535-7163.MCT-19-0170. Epub 2019 Aug 22. Mol Cancer Ther. 2019. PMID: 31439712
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response.
Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, Zhang C, Schnell C, Yang G, Zhang Y, Balbin OA, Barbe S, Cai H, Casey F, Chatterjee S, Chiang DY, Chuai S, Cogan SM, Collins SD, Dammassa E, Ebel N, Embry M, Green J, Kauffmann A, Kowal C, Leary RJ, Lehar J, Liang Y, Loo A, Lorenzana E, Robert McDonald E 3rd, McLaughlin ME, Merkin J, Meyer R, Naylor TL, Patawaran M, Reddy A, Röelli C, Ruddy DA, Salangsang F, Santacroce F, Singh AP, Tang Y, Tinetto W, Tobler S, Velazquez R, Venkatesan K, Von Arx F, Wang HQ, Wang Z, Wiesmann M, Wyss D, Xu F, Bitter H, Atadja P, Lees E, Hofmann F, Li E, Keen N, Cozens R, Jensen MR, Pryer NK, Williams JA, Sellers WR. Gao H, et al. Among authors: williams ja. Nat Med. 2015 Nov;21(11):1318-25. doi: 10.1038/nm.3954. Epub 2015 Oct 19. Nat Med. 2015. PMID: 26479923
A Proof of Concept for Biomarker-Guided Targeted Therapy against Ovarian Cancer Based on Patient-Derived Tumor Xenografts.
Palmer AC, Plana D, Gao H, Korn JM, Yang G, Green J, Zhang X, Velazquez R, McLaughlin ME, Ruddy DA, Kowal C, Muszynski J, Bullock C, Rivera S, Rakiec DP, Elliott G, Fordjour P, Meyer R, Loo A, Kurth E, Engelman JA, Bitter H, Sellers WR, Williams JA, Sorger PK. Palmer AC, et al. Among authors: williams ja. Cancer Res. 2020 Oct 1;80(19):4278-4287. doi: 10.1158/0008-5472.CAN-19-3850. Epub 2020 Aug 3. Cancer Res. 2020. PMID: 32747364 Free PMC article.
Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ, Mulford IJ, Sharp F, Liang J, Kurtulus S, Trabucco G, Quinn DS, Longmire TA, Patel N, Patil R, Shirley MD, Chen Y, Wang H, Ruddy DA, Fabre C, Williams JA, Hammerman PS, Mataraza J, Platzer B, Halilovic E. Wang HQ, et al. Among authors: williams ja. Cancer Res. 2021 Jun 1;81(11):3079-3091. doi: 10.1158/0008-5472.CAN-20-0189. Epub 2021 Jan 27. Cancer Res. 2021. PMID: 33504557
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Buonamici S, Williams J, Morrissey M, Wang A, Guo R, Vattay A, Hsiao K, Yuan J, Green J, Ospina B, Yu Q, Ostrom L, Fordjour P, Anderson DL, Monahan JE, Kelleher JF, Peukert S, Pan S, Wu X, Maira SM, García-Echeverría C, Briggs KJ, Watkins DN, Yao YM, Lengauer C, Warmuth M, Sellers WR, Dorsch M. Buonamici S, et al. Among authors: williams j. Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599. Sci Transl Med. 2010. PMID: 20881279 Free PMC article.
18,749 results
You have reached the last available page of results. Please see the User Guide for more information.